North Dakota State Investment Board Purchases New Shares in Boston Scientific Corporation $BSX

Posted by on May 18th, 2026

North Dakota State Investment Board acquired a new position in Boston Scientific Corporation (NYSE:BSX – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 50,618 shares of the medical equipment provider’s stock, valued at approximately $4,826,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BSX. Murphy & Mullick Capital Management Corp increased its position in Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares during the period. FWL Investment Management LLC acquired a new stake in Boston Scientific in the second quarter worth about $26,000. United Community Bank increased its position in Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 147 shares during the period. Colonial Trust Co SC increased its position in Boston Scientific by 502.2% in the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 231 shares during the period. Finally, Bangor Savings Bank increased its position in Boston Scientific by 94.7% in the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 142 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Trading Down 0.0%

Shares of NYSE BSX opened at $52.67 on Monday. The company’s fifty day moving average is $63.40 and its 200-day moving average is $81.65. The stock has a market cap of $78.27 billion, a price-to-earnings ratio of 22.04, a P/E/G ratio of 0.97 and a beta of 0.62. Boston Scientific Corporation has a twelve month low of $52.52 and a twelve month high of $109.50. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX – Get Free Report) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The company had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period last year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts predict that Boston Scientific Corporation will post 3.38 EPS for the current year.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of research reports. Daiwa Securities Group lowered Boston Scientific from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Raymond James Financial reiterated an “outperform” rating and issued a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. Needham & Company LLC lowered their price objective on Boston Scientific from $97.00 to $77.00 and set a “buy” rating for the company in a research report on Thursday, April 23rd. Weiss Ratings lowered Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday. Finally, UBS Group lowered their price objective on Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a research report on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $93.91.

Check Out Our Latest Research Report on BSX

Boston Scientific Company Profile

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.

Read More

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.